← Research library

Preclinical Pharmacokinetics of GZK-111, a Dipeptide with Neuroprotective Activity.

Animal research · 2022

What was studied
Rats; intravenous and intragastric pharmacokinetics
Main finding
GZK-111 underwent extensive conversion to CPG in rats. CPG persisted more than twice as long in plasma and reached higher concentrations than the parent compound.

Study data at a glance

Participants or experimental model
Rats; intravenous and intragastric pharmacokinetics
Reported results
GZK-111 underwent extensive conversion to CPG in rats. CPG persisted more than twice as long in plasma and reached higher concentrations than the parent compound.
Study limitations and source details

Study limitations

  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Source details

Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.

Abstract reviewed

Sources checked

Citation

Animal / experimentalEnglish abstract

Litvin AA, Kolyvanov GB, Bochkov PO, Shevchenko RV, Podol'ko AL, Kolyasnikova KN, Zherdev VP. Preclinical Pharmacokinetics of GZK-111, a Dipeptide with Neuroprotective Activity. Bulletin of experimental biology and medicine

Study source ↗ · DOI 10.1007/s10517-022-05400-x · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards